These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

902 related items for PubMed ID: 9704715

  • 1. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D.
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [Abstract] [Full Text] [Related]

  • 2. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N, National Cancer Institute of Canada Clinical Trials Group.
    J Clin Oncol; 2005 Aug 01; 23(22):5166-70. PubMed ID: 16051958
    [Abstract] [Full Text] [Related]

  • 3. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP, Anton A, Breitbach GP, Colajori E, Tursi JM, Delfino C, Efremidis A, Ezzat A, Fittipaldo A, Kolaric K, Lopez M, Viaro D, HEPI 013 study group.
    J Clin Oncol; 2001 Feb 15; 19(4):943-53. PubMed ID: 11181656
    [Abstract] [Full Text] [Related]

  • 4. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y, Adjuvant CEF Research Group for Breast Cancer.
    Breast Cancer; 2010 Jul 15; 17(3):190-8. PubMed ID: 19575284
    [Abstract] [Full Text] [Related]

  • 5. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
    Radice D, Redaelli A.
    Pharmacoeconomics; 2005 Jul 15; 23(1):69-75. PubMed ID: 15693729
    [Abstract] [Full Text] [Related]

  • 6. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC, Bliss JM, Wils J, Morvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-López FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M.
    J Clin Oncol; 1996 Jan 15; 14(1):35-45. PubMed ID: 8558217
    [Abstract] [Full Text] [Related]

  • 7. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K.
    J Clin Oncol; 2003 Aug 15; 21(16):3066-71. PubMed ID: 12915595
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK.
    Cancer; 2000 Dec 15; 89(12):2521-6. PubMed ID: 11135211
    [Abstract] [Full Text] [Related]

  • 9. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM, TACT2 Investigators.
    Lancet Oncol; 2017 Jul 15; 18(7):929-945. PubMed ID: 28600210
    [Abstract] [Full Text] [Related]

  • 10. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.
    Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM.
    J Clin Oncol; 2001 Jun 15; 19(12):3103-10. PubMed ID: 11408507
    [Abstract] [Full Text] [Related]

  • 11. Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).
    Wils J, Coombes RC, Marty M, Bliss J, Woods E.
    Drugs; 1993 Jun 15; 45 Suppl 2():46-50; discussion 49-50. PubMed ID: 7693422
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P, Kerbrat P, Romestaing P, Fargeot P, Brémond A, Namer M, Schraub S, Goudier MJ, Mihura J, Monnier A, Clavère P, Serin D, Seffert P, Pourny C, Facchini T, Jacquin JP, Sztermer JF, Datchary J, Ramos R, Luporsi E.
    J Clin Oncol; 2003 Jan 15; 21(2):298-305. PubMed ID: 12525522
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B, Mouridsen HT, Jensen MB.
    Acta Oncol; 2008 Jan 15; 47(4):662-71. PubMed ID: 18465334
    [Abstract] [Full Text] [Related]

  • 14. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
    Levine MN, Bramwell V, Pritchard K, Perrault D, Findlay B, Abu-Zahra H, Warr D, Arnold A, Skillings J.
    Eur J Cancer; 1992 Jan 15; 29A(1):37-43. PubMed ID: 1445744
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P.
    Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820
    [Abstract] [Full Text] [Related]

  • 16. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL, Gelman RS, Hayes DF, Osteen R, Obando A, Canellos GP, Frei E, Henderson IC.
    J Natl Cancer Inst; 1993 May 19; 85(10):812-7. PubMed ID: 8487326
    [Abstract] [Full Text] [Related]

  • 17. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B, Zoladex Early Breast Cancer Research Association Study.
    J Clin Oncol; 2002 Dec 15; 20(24):4628-35. PubMed ID: 12488406
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ, Maibach R, Castiglione M, Jungi WF, Cavalli F, Leyvraz S, Obrecht JP, Schildknecht O, Siegenthaler P.
    J Clin Oncol; 1997 Jul 15; 15(7):2502-9. PubMed ID: 9215818
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.